Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (vol 18, pg 1493, 2017)

被引：0
|
作者：
Tawbi, H. A.
Burgess, M.
Bolejack, V
机构：
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E711 / E711
页数：1
相关论文
共 50 条
  • [31] Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial
    Guadagnolo, B. Ashleigh
    Bassett, Roland L.
    Mitra, Devarati
    Farooqi, Ahsan
    Hempel, Caroline
    Dorber, Courtney
    Willis, Tiara
    Wang, Wei-Lien
    Ratan, Ravin
    Somaiah, Neeta
    Benjamin, Robert S.
    Torres, Keila E.
    Hunt, Kelly K.
    Scally, Christopher P.
    Keung, Emily Z.
    Satcher, Robert L.
    Bird, Justin E.
    Lin, Patrick P.
    Moon, Bryan S.
    Lewis, Valerae O.
    Roland, Christina L.
    Bishop, Andrew J.
    LANCET ONCOLOGY, 2022, 23 (12): : 1547 - 1557
  • [32] A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas
    Wilky, Breelyn A.
    Maleddu, Alessandra
    Mailhot, Anne
    Cartwright, Chelsey
    Gao, Dexiang
    Tellez, Cristiam Moreno
    Powers, Kyle
    Kemp, Lindsey
    Therrien, Nicholas
    Patel, Jaymin M.
    Grossman, Joseph Elan
    O'Day, Steven
    Elias, Anthony D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
    Perez-Garcia, Jose M.
    Llombart-Cussac, Antonio
    Cortes, Maria G.
    Curigliano, Giuseppe
    Lopez-Miranda, Elena
    Alonso, Jose L.
    Bermejo, Begona
    Calvo, Lourdes
    Caranana, Vicente
    de la Cruz Sanchez, Susana
    Vazquez, Raul M.
    Prat, Aleix
    Borrego, Manuel R.
    Sampayo-Cordero, Miguel
    Segui-Palmer, Miguel A.
    Soberino, Jesus
    Malfettone, Andrea
    Schmid, Peter
    Cortes, Javier
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394
  • [34] Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
    Kawazoe, Akihito
    Fukuoka, Shota
    Nakamura, Yoshiaki
    Kuboki, Yasutoshi
    Wakabayashi, Masashi
    Nomura, Shogo
    Mikamoto, Yuichi
    Shima, Hikari
    Fujishiro, Noriko
    Higuchi, Tsukiko
    Sato, Akihiro
    Kuwata, Takeshi
    Shitara, Kohei
    LANCET ONCOLOGY, 2020, 21 (08): : 1057 - 1065
  • [35] Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial (vol 7, pg 93, 2019)
    Whyte, M. P.
    Simmons, J. H.
    Moseley, S.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (02): : E2 - E2
  • [36] Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (vol 18, pg 812, 2017)
    Gronchi, A.
    Ferrari, S.
    Quagliuolo, V
    LANCET ONCOLOGY, 2017, 18 (06): : E301 - E301
  • [37] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study (vol 22, pg 919, 2021)
    Balar, Arjun V.
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    LANCET ONCOLOGY, 2021, 22 (08): : E347 - E347
  • [38] Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT
    Ferolla, P.
    Berruti, A.
    Fazio, N.
    Mazzanti, P.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 196 - 196
  • [39] An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
    Schoffski, P.
    Adkins, D.
    Blay, J. -Y.
    Gil, T.
    Elias, A. D.
    Rutkowski, P.
    Pennock, G. K.
    Youssoufian, H.
    Gelderblom, H.
    Willey, R.
    Grebennik, D. O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3219 - 3228
  • [40] Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial (vol 21, pg 645, 2020)
    Trigo, J.
    Subbiah, V
    Besse, B.
    LANCET ONCOLOGY, 2020, 21 (12): : E553 - E553
12345